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Abstract
Background: THK5351 and flortaucipir tau ligands have high affinity for paired helical filament tau, yet diverse off-
target bindings have been reported. Recent data support the hypothesis that THK5351 binds to monoamine
oxidase B (MAO-B) expressed from reactive astrocytes and that flortaucipir has an affinity toward MAO-A and B;
however, pathological evidence is lacking. We performed a head-to-head comparison of the two tau ligands in a
sporadic Creutzfeldt-Jakob disease (CJD) patient and performed an imaging-pathological correlation study.
Case presentation: A 67-year-old man visited our clinic a history of 6months of rapidly progressive dementia, visual
disturbance, and akinetic mutism. Diffusion-weighted imaging showed cortical diffusion restrictions in the left temporo-
parieto-occipital regions. 18F-THK5351 PET, but not 18F-flortaucipir PET showed high uptake in the left temporo-parieto-
occipital regions, largely overlapping with the diffusion restricted areas. Cerebrospinal fluid analysis was weakly
positive for 14–3-3 protein and pathogenic prion protein was found. The patient showed rapid cognitive decline
along with myoclonic seizures and died 13months after his first visit. A post-mortem study revealed immunoreactivity
for PrPsc, no evidence of neurofibrillary tangles, and abundant astrocytosis which was reactive for MAO-B antibody.
Conclusions: Our findings add pathological evidence that increased THK5351 uptake in sporadic CJD patients might
be caused by an off-target binding driven by its high affinity for MAO-B.
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Background
THK5351 and flortaucipir tau ligands were developed
with the anticipation that they would have specific high
affinity for paired helical filament (PHF) type tau, the
building blocks of neurofibrillary tangles (NFT) in
Alzheimer’s disease. Yet, diverse off-target binding has
been reported on positron emission tomography (PET)
imaging for each ligand [1]. Accumulating data support the
hypothesis that THK5351, a quinolone-derivative agent,
binds to monoamine oxidase B (MAO-B) expressed from
reactive astrocytes [2]. Flortaucipir has also shown in vitro
affinity toward MAO-A and B [3]. In addition, a recent
head-to-head comparison of two tau ligands raised the
possibility that THK5351 and flortaucipir have distinct
characteristics [4].
Sporadic Creutzfeldt-Jakob disease (sCJD), caused by
prion protein, is a rapidly progressive neurodegenerative
disorder that can have increased MAO-B activity as well
as NFT. Previous imaging and pathology studies of CJD
showed increased MAO-B expression by activated astro-
cytes and microglia [5, 6]. Meanwhile, various neuronal
and glial tau pathologies exist in sCJD patients, including
NFT, and the co-existence of Alzheimer’s disease occurs
in 10% of patients with sCJD [7, 8]. Cerebrospinal fluid
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(CSF) analysis of CJD patients shows highly elevated
total tau and slightly elevated phosphorylated tau [9].
In the present study, we performed a head-to-head
comparison of two tau (THK5351 and flortaucipir) PET
images in a patient with sCJD to find out whether the
patient’s brain showed distinct uptake patterns. We fur-
ther performed an imaging-pathological correlation study
to determine whether increased uptake of tau ligands in
this case represented increased PHF-type tau burden or
MAO-B activity.
Case presentation
A 67-year-old right-handed man with a history of hyper-
tension visited the Memory Clinic at Samsung Medical
Center for rapidly progressive dementia, visual disturb-
ance, and akinetic mutism, which started six months prior
to his first visit. On neurologic examination, he showed
bilateral bradykinesia, parkinsonian gait, and postural in-
stability. On neuropsychological tests, his Mini-Mental
State Examination score was 21 (6 years of formal educa-
tion). He showed poor performance on language (confron-
tational naming, comprehension, and repetition tests),
visuospatial, memory, and frontal/executive function.
CSF analysis showed that white blood cell count, red
blood cell count, protein and glucose levels were all nor-
mal. However, 14–3-3 protein was weakly positive, total
tau was highly elevated (1081.9 pg/ml, normal range
116–370 pg/ml), and phosphorylated tau was mildly ele-
vated (87.0 pg/ml, normal range 35.84–66.26 pg/ml). Amyl-
oid-ß was within the normal range (910.0 pg/ml, normal
range 562–1018 pg/ml). Pathogenic prion protein (PrPSc)
was found using a RT-QuIC assay; however, the PRNP
mutation was not found. Diffusion-weighted imaging
(DWI) showed cortical diffusion restrictions in the left
temporo-parieto-occipital regions (Fig. 1a). Based on
his clinical symptoms and laboratory tests, the patient
was diagnosed with probable sCJD.
The patient further underwent molecular PET imaging
using ligands that bind to amyloid (18F-florbetaben) and
PHF tau (18F-Flortaucipir and 18F-THK5351). 18F-florbe-
taben PET revealed amyloid negative. 18F-Flortaucipir
PET showed focal uptake only in the left occipital white
matter region. However, 18F-THK5351 PET showed diffuse
high uptake on the left temporo-parieto-occipital regions,
which largely overlapped with the diffusion restricted areas
(Fig. 1a). To quantitatively measure tau uptake, we deter-
mined the voxel-wise ROI of diffusion restricted regions by
hand-drawing using MRIcro (https://www.mccausland
center.sc.edu/crnl/). We calculated the standardized
uptake value ratio (SUVR) of each THK5351, flortau-
cipir, and florbetaben uptake in diffusion restricted
and unrestricted voxels. Then, to analyze whether the
diffusion restricted area showed higher tau uptake, we
parcellated the whole cerebral cortex into 84 regions
based on an AAL template. We manually classified
each parcellated region as a diffusion restricted area
when more than 50% of the region showed diffusion
restriction or as a diffusion non-restricted area when
less than 50% of the region showed diffusion restriction.
We then compared the regional SUVR of THK5351,
flortaucipir, and florbetaben between diffusion re-
stricted and non-restricted areas. We found that the
mean THK5351 SUVR of diffusion restricted voxels
was 2.17 whereas the mean THK5351 SUVR of diffu-
sion non-restricted voxels was 1.79. The mean flortau-
cipir SUVR of diffusion restricted voxels was 1.16
whereas the mean flortaucipir SUVR of diffusion non-
restricted voxels was 1.20. The mean forbetaben SUVR
of diffusion restricted voxels was 1.07 whereas the
mean florbetaben SUVR of diffusion non-restricted
voxels was 1.16. Quantitative analyses showed that
THK5351 standardized uptake value ratio (SUVR) in
diffusion restricted areas was higher compared to diffu-
sion non-restricted areas, while flortaucipir SUVR and
florbetaben SUVR did not show any difference (Fig. 1b)
(Additional file 1).
The patient died 13months after his first visit and
underwent brain autopsy. The time interval between im-
aging scans and autopsy was approximately 13months
(399 days for MRI, 396 days for florbetaben PET, 388 days
for flortaucipir PET, and 378 days for THK5351 PET).
Neuropathological analysis was performed at Chuncheon
Sacred Heart Hospital, Chuncheon, Korea. Autopsies were
performed according to the standard protocols of National
Neuropathology Reference and Diagnostic Laboratories for
Dementia (NRD) supported by Korea National Institute of
Health [10, 11]. Neuropathological diagnostic analysis was
performed on sections, including the frontal, occipital, and
basal ganglia of the right and left hemisphere. For each
immunohistochemical stain, the degree of pathology was
graded as none, mild (< 10%), moderate (10–30%), or severe
(> 30%).
A post-mortem study confirmed the diagnosis of CJD,
as we found neuronal loss and micro-vacuolar degener-
ation on H&E (Fig. 2a) and immunoreactive for PrPsc
(3F4 and 1C5 antibody) (Fig. 2b-c). There was no evi-
dence of neuritic plaques (Fig. 2d) or NFT (Fig. 2e) in
the bilateral frontal, occipital cortices, and basal ganglia.
However, we found mild diffuse amyloid plaques and
mild neuropil threads. Glial fibrillary acidic protein
(GFAP) stain showed the following results: moderate re-
activity in the bilateral frontal and left occipital cortices;
mild reactivity in the right occipital cortex and left basal
ganglia; and non-reactivity in the right basal ganglia
(Fig. 2f). MAO-B stain showed severe reactivity in the
left frontal and bilateral occipital cortices and moder-
ate reactivity in the right frontal cortex and bilateral
basal ganglia (Fig. 2g).
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Fig. 2 Pathological findings in the left occipital cortex of a patient with sporadic Creutzfeldt-Jakob disease. H&E staining (a) showed neuronal loss
and vacuolation. Immunohistochemistry showed reactivity for PrPsc, b 3F4 antibody and c 1C5 antibody. Immunohistochemistry against amyloid-
ß (d) and phosphorylated tau (e) showed no amyloid plaques and no neurofibrillary tangles, respectively. GFAP staining (f) showed active
astrocytosis and MAO-B staining (g) showed increased MAO-B activity
Fig. 1 a Diffusion weighted images (DWI), apparent diffusion coefficient (ADC), tau (THK5351 and flortaucipir, and amyloid (florbetaben) PET
images in a patient with sporadic Creutzfeldt-Jakob disease. b Regional standardized uptake value ratio (SUVR) of THK5351, flortaucipir, and
florbetaben in diffusion non-restricted and restricted areas
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Discussion and conclusions
We report the PET findings of two tau ligands (flortaucipir
and THK5351) and the autopsy results in a patient with
sCJD. Our novel finding was that THK5351 uptake was
increased in regions similar to diffusion restricted cortical
areas, while flortaucipir uptake was not. The post-mortem
study revealed no NFT but severe astrocytosis which was
reactive for MAO-B staining. Therefore, our findings add
pathological evidence that flortaucipir is more specific to
PHF tau, and increased THK5351 uptake in sCJD might be
an off-target binding driven by its high affinities to MAO-B.
These two tau ligands showed different uptake pat-
terns in our patient with CJD. THK5351 uptake was in-
creased in regions similar to diffusion restricted cortical
areas, while flortaucipir uptake was not. Our finding is
consistent with a recent study showing that CJD patients
did not have any increased uptakes of flortaucipir [12].
Our imaging-pathological correlation study showed that
there were mild neurophil threads but no NFT, suggest-
ing that increased uptakes of THK5351 might represent
off-target bindings. Indeed, previous studies showed that
increased CSF tau in CJD is related to increased burdens
of dystrophic neurites due to rapid destruction of neu-
rons rather than development of PHF-type tau [7]. Our
results are in line with our previous head to head com-
parison of the two ligands showing that flortaucipir is
more sensitive and specific to PHF-type tau than
THK5351 [4].
The underlying pathological substrate for THK5351
uptake in CJD might be related to increased MAO-B ac-
tivity. We observed that GFAP staining of the region
with diffusion restriction and high THK5351 uptake
showed severe astrocytosis which was reactive for MAO-
B staining. Our results are in line with previous reports
showing sCJD patients have increased reactive astrocytes
and MAO-B activity in the brain [5]. Previous studies
suggested that THK5351 has high affinity for MAO-B,
as ingestion of MAO-B inhibitor (selegiline) reduced
THK5351 uptake [2], whereas MAO-B inhibitor did not
block flortaucipir uptake in human brains [13]. Our
findings, therefore, suggested that increased THK5351
uptake in this case might represent increased MAO-B
activity within increased reactive astrocytosis.
Although THK5351 uptake regions largely overlapped
with diffusion restricted areas, left frontal region showed
discrepancy. The discrepancy between negative DWI
and positive THK5351 uptake in the left frontal region
might be explained by the difference in the underlying
pathological substrate. Previous pathological studies
showed that diffusion restriction on DWI correlated best
with spongiform changes and PrP deposition, followed
by reactive astrocytic gliosis [14, 15]. On the other hand,
THK5351 uptake reflects increased MAO-B activity and
increased reactive astrocytosis. Although autopsy findings
in the left frontal region showed advanced features of
sCJD (neuronal loss, micro-vacuolar degeneration, PrPsc
immunoreactivity, moderate reactivity on GFAP staining,
and severe reactivity on MAO-B staining), we assume that
at the time the patient underwent brain imaging, this re-
gion might have had astrocytosis with increased MAO-B
activity but not spongiform changes or PrP deposition.
The limitation of this study is the 13-month delay be-
tween imaging scans and autopsy. As histopathological
data were obtained at a more advanced stage than im-
aging data, vacuolation, PrPsc deposition, and reactive
astrocytic gliosis with increased MAO-B activity were
likely less severe at the time the patient underwent im-
aging. Therefore, DWI and THK5351 might not fully re-
flect the pathological findings. However, as there was no
evidence of neuritic plaques or NFT even at the ad-
vanced stage, we conclude that THK5351 uptake in this
sCJD patient represents off-target binding.
In conclusion, our imaging-pathological correlation
study of THK5351 and flortaucipir suggested that flor-
taucipir is more specific to PHF tau, and increased
THK5351 uptake in sCJD might be an off-target binding
driven by its high affinities to MAO-B.
Additional file
Additional file 1: Supplementary Methods. Detailed methods for PET
acquisition and analysis. (DOCX 15 kb)
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